Muna Therapeutics Announces CEO Transition as Clinical Pipeline Advances

Muna Therapeutics, a biotechnology company pioneering novel therapeutics for neurodegenerative diseases, announced a CEO transition. Rita Balice-Gordon, Ph.D., Muna's founding CSO and CEO since 2021, will step down and join the Company's Board of Directors. Michel Detheux, Ph.D., a seasoned biotech entrepreneur and former President and CEO of iTeos Therapeutics , has been appointed CEO, effective June 29, 2026.

"Rita and the team have built a platform and pipeline unlike anything else in neurodegeneration," said Michel Detheux, Ph.D., incoming Chief Executive Officer. "Their exceptional work has yielded a compelling clinical asset in the TREM2 agonist program and a major validation of the MiND-MAP platform through the GSK alliance, a partnership model I know well. I am honored to take the helm at this moment and work alongside the team to advance Muna's promising pipeline for people living with neurodegenerative diseases."

"On behalf of the entire Board, I want to express our profound gratitude to Rita for her leadership in shaping Muna into the company it is today," said Donald Nicholson, Ph.D., Chair of Muna's Board of Directors. "Her scientific vision, drive, and deep commitment to patients have been foundational to what we have achieved. We are delighted that she will continue to contribute her unique perspective as a Board member and extremely pleased to welcome Michel, whose business experience and acumen will be instrumental in guiding Muna through future clinical and corporate milestones."